Physician profile
Thomas C Jones
NPI 1740208966
$37,701.31
in general payments reported to CMS, 2019-2025
58 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,505 · 2020: $3,777 · 2021: $20K · 2022: $2,181 · 2023: $1,977 · 2024: $1,733 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,165 · Education: $56.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,165.27 |
| Education | $56.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $23,409.37 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,809.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,506.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $1,113.21 | 2021-2023 | Intellis Adaptivestim |
| Eli Lilly and Company | $1,047.25 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $701.01 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $564.83 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $495.46 | 2019-2025 | Freestyle Libre |
| Insulet Corporation | $469.19 | 2019-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $455.40 | 2021-2025 | |
| Amgen INC. | $437.94 | 2019-2025 | Tepezza, Repatha |
| Corcept Therapeutics | $402.47 | 2019-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $398.19 | 2019-2025 | Unithroid |
| Horizon Therapeutics Plc | $366.72 | 2019-2023 | Tepezza |
| Antares Pharma, INC. | $355.34 | 2019-2025 | Xyosted |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.80 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Janssen Pharmaceuticals, INC | $310.85 | 2019-2020 | |
| Abbvie INC. | $310.05 | 2019-2025 | |
| Radius Health, INC. | $259.31 | 2019-2025 | Tymlos |
| Zealand Pharma US, INC. | $248.08 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.81 | 2021-2024 | |
| Cequr Corporation | $196.72 | 2022-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $184.65 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals LP | $153.09 | 2019-2022 | |
| Ibsa Pharma INC. | $144.17 | 2019-2023 | Tirosint, Licart |
| Alexion Pharmaceuticals, INC. | $139.25 | 2019-2024 | Strensiq |
| Valeritas, INC. | $138.46 | 2019 | |
| Embecta Corp. | $117.90 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Amarin Pharma, INC. | $113.66 | 2019-2020 | |
| Esperion Therapeutics, INC. | $109.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $104.39 | 2019-2020 | |
| Mannkind Corporation | $93.03 | 2022-2024 | |
| Dexcom, INC. | $85.63 | 2019-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $85.56 | 2023-2024 | Crysvita |
| Tolmar, INC. | $70.50 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.29 | 2022-2023 | Cycloset |
| Becton, Dickinson and Company | $68.09 | 2019-2021 | |
| Senseonics, Incorporated | $64.00 | 2019-2020 | |
| Halozyme INC | $61.80 | 2023 | |
| Companion Medical, INC. | $58.96 | 2019 | |
| Medtronic Minimed, INC. | $53.52 | 2019-2020 | |
| Madrigal Pharmaceuticals | $41.56 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $41.27 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $41.18 | 2019-2021 | |
| Shire North American Group INC | $36.74 | 2019 | |
| Ascendis Pharma Endocrinology INC | $35.50 | 2025 | Yorvipath |
| Bigfoot Biomedical INC | $33.45 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $22.26 | 2021 | |
| Amryt Pharma Holdings LTD | $20.63 | 2022 | |
| Boston Scientific Corporation | $19.00 | 2024 | |
| Pfizer INC. | $18.31 | 2024 | |
| Ionis Pharmaceuticals, INC. | $15.56 | 2025 | Tryngolza |
| Sun Pharmaceutical Industries INC. | $13.91 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $13.23 | 2024 | Imcivree |
| Clarus Therapeutics INC. | $10.34 | 2021 | |
| Vivus LLC | $8.95 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$73,093.89 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.